Arecor Therapeutics (LSE:AREC) Total Stockholders Equity : £9.53 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics Total Stockholders Equity?

Arecor Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £9.53 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Arecor Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 was £0.31. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Arecor Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.04.

Arecor Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Arecor Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arecor Therapeutics Total Stockholders Equity Chart

Arecor Therapeutics Annual Data

Trend

May17

May18

May19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

4.22

0.77

18.55

17.46

9.53

Arecor Therapeutics Semi-Annual Data
	May18	May19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Stockholders Equity	Get a 7-Day Free Trial					18.55	14.58	17.46	13.21	9.53

Arecor Therapeutics (LSE:AREC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Arecor Therapeutics's Book Value per Share for the quarter that ended in Dec. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(9.527	-	0)	/	30.627
	=	0.31

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Arecor Therapeutics's Debt-to-Equity for the quarter that ended in Dec. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.118	+	0.22)	/	9.527
	=	0.04

Arecor Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Arecor Therapeutics (LSE:AREC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

6UI:Germany

Address

Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL

Website

https://www.arecor.com

Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.